Zymeworks Inc. (ZYME)
ZYME Stock Price Chart
Explore Zymeworks Inc. interactive price chart. Choose custom timeframes to analyze ZYME price movements and trends.
ZYME Company Profile
Discover essential business fundamentals and corporate details for Zymeworks Inc. (ZYME) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Apr 2017
Employees
299.00
Website
https://www.zymeworks.comCEO
Kenneth H. Galbraith
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
ZYME Financial Timeline
Browse a chronological timeline of Zymeworks Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 30 Oct 2025
EPS estimate is -$0.32.
Earnings released on 7 Aug 2025
EPS came in at $0.03 surpassing the estimated -$0.52 by +105.77%, while revenue for the quarter reached $48.73M , beating expectations by +89.26%.
Earnings released on 8 May 2025
EPS came in at -$0.30 surpassing the estimated -$0.45 by +33.33%, while revenue for the quarter reached $27.11M , beating expectations by +50.42%.
Earnings released on 5 Mar 2025
EPS came in at -$0.31 falling short of the estimated $0.01 by -3.20K%, while revenue for the quarter reached $31.03M , beating expectations by +104.15%.
Earnings released on 31 Oct 2024
EPS came in at -$0.39 surpassing the estimated -$0.40 by +2.50%, while revenue for the quarter reached $16.00M , missing expectations by -66.01%.
Earnings released on 1 Aug 2024
EPS came in at -$0.49 falling short of the estimated -$0.42 by -17.37%, while revenue for the quarter reached $19.24M , beating expectations by +61.22%.
Earnings released on 2 May 2024
EPS came in at -$0.42 falling short of the estimated -$0.31 by -35.48%, while revenue for the quarter reached $10.03M , missing expectations by -42.74%.
Earnings released on 6 Mar 2024
EPS came in at -$0.20 surpassing the estimated -$0.39 by +48.72%, while revenue for the quarter reached $16.93M , missing expectations by -4.18%.
Earnings released on 7 Nov 2023
EPS came in at -$0.41 surpassing the estimated -$0.55 by +25.45%, while revenue for the quarter reached $16.51M , beating expectations by +12.80%.
Earnings released on 10 Aug 2023
EPS came in at -$0.76 falling short of the estimated -$0.51 by -49.02%, while revenue for the quarter reached $7.00M , missing expectations by -76.17%.
Earnings released on 8 May 2023
EPS came in at -$0.37 surpassing the estimated -$0.64 by +42.19%, while revenue for the quarter reached $35.58M , beating expectations by +83.07%.
Earnings released on 7 Mar 2023
EPS came in at $4.65 falling short of the estimated $4.84 by -3.93%, while revenue for the quarter reached $402.49M , beating expectations by +87.76%.
Earnings released on 8 Nov 2022
EPS came in at -$0.72 surpassing the estimated -$0.94 by +23.40%, while revenue for the quarter reached $2.63M , missing expectations by -33.18%.
Earnings released on 4 Aug 2022
EPS came in at -$0.97 falling short of the estimated -$0.93 by -4.30%, while revenue for the quarter reached $5.44M , missing expectations by -23.22%.
Earnings released on 4 May 2022
EPS came in at -$1.19 falling short of the estimated -$0.97 by -22.68%, while revenue for the quarter reached $1.92M .
Earnings released on 24 Feb 2022
EPS came in at -$0.95 surpassing the estimated -$1.06 by +10.38%, while revenue for the quarter reached $19.87M , beating expectations by +146.53%.
Earnings released on 3 Nov 2021
EPS came in at -$1.25 falling short of the estimated -$1.18 by -5.93%, while revenue for the quarter reached $4.40M , missing expectations by -43.29%.
Earnings released on 4 Aug 2021
EPS came in at -$1.31 falling short of the estimated -$1.06 by -23.58%, while revenue for the quarter reached $1.77M , missing expectations by -75.06%.
Earnings released on 5 May 2021
EPS came in at -$0.87 surpassing the estimated -$1.02 by +14.71%, while revenue for the quarter reached $644.00K , missing expectations by -90.94%.
Earnings released on 24 Feb 2021
EPS came in at -$0.74 surpassing the estimated -$1.21 by +38.84%, while revenue for the quarter reached $15.68M , beating expectations by +52.23%.
Earnings released on 3 Nov 2020
EPS came in at -$1.43 falling short of the estimated -$0.92 by -55.43%, while revenue for the quarter reached $2.64M , missing expectations by -79.22%.
ZYME Stock Performance
Access detailed ZYME performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.